More generally, CCR7 signalling upon binding to its ligands (CCL19/21) is associated with many pro-tumorigenic effects in hematological malignancies, including migration, proliferation, survival and immune evasion (Cuesta-Mateos et al., 2021). Here, CCR7 is linked to hematologic disorder.